Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor
activity and safety of bemcentinib when given in combination with pembrolizumab in up to 106
participants with previously treated, advanced adenocarcinoma of the lung. The study will
enroll three cohorts of participants with previously treated, advanced adenocarcinoma of the
lung: Cohort A will consist of participants who received a maximum of 1 prior line of
platinum-containing chemotherapy and no prior immunotherapy of any kind. Cohort B will
consist of participants who received a maximum of one prior line of an anti-programmed death
receptor (PD)-(L)1 therapy (monotherapy). Cohort C will consist of participants who received
a maximum of one prior line of therapy with an anti-PD-(L)1 therapy in combination with a
platinum-containing chemotherapy.The primary objective is to assess the anti-tumor activity
of bemcentinib and pembrolizumab when given in combination.